214 related articles for article (PubMed ID: 10617083)
21. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
22. A mammalianized synthetic nitroreductase gene for high-level expression.
Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ
BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451
[TBL] [Abstract][Full Text] [Related]
23. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
[TBL] [Abstract][Full Text] [Related]
24. A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.
Hay MP; Sykes BM; Denny WA; Wilson WR
Bioorg Med Chem Lett; 1999 Aug; 9(15):2237-42. PubMed ID: 10465553
[TBL] [Abstract][Full Text] [Related]
25. PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
Güngör T; Önder FC; Tokay E; Gülhan ÜG; Hacıoğlu N; Tok TT; Çelik A; Köçkar F; Ay M
Eur J Med Chem; 2019 Jun; 171():383-400. PubMed ID: 30928710
[TBL] [Abstract][Full Text] [Related]
26. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
[TBL] [Abstract][Full Text] [Related]
27. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
[TBL] [Abstract][Full Text] [Related]
28. Advances in imaging gene-directed enzyme prodrug therapy.
Bhaumik S
Curr Pharm Biotechnol; 2011 Apr; 12(4):497-507. PubMed ID: 21342105
[TBL] [Abstract][Full Text] [Related]
29. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
30. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
31. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
Friedlos F; Denny WA; Palmer BD; Springer CJ
J Med Chem; 1997 Apr; 40(8):1270-5. PubMed ID: 9111301
[TBL] [Abstract][Full Text] [Related]
32. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Benouchan M; Do Nascimento F; Perret GY; Colombo BM
Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
[TBL] [Abstract][Full Text] [Related]
33. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
34. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
35. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.
Jaberipour M; Vass SO; Guise CP; Grove JI; Knox RJ; Hu L; Hyde EI; Searle PF
Biochem Pharmacol; 2010 Jan; 79(2):102-11. PubMed ID: 19665450
[TBL] [Abstract][Full Text] [Related]
36. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.
Anlezark GM; Melton RG; Sherwood RF; Wilson WR; Denny WA; Palmer BD; Knox RJ; Friedlos F; Williams A
Biochem Pharmacol; 1995 Aug; 50(5):609-18. PubMed ID: 7669063
[TBL] [Abstract][Full Text] [Related]
37. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
[TBL] [Abstract][Full Text] [Related]
38. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).
Singleton DC; Li D; Bai SY; Syddall SP; Smaill JB; Shen Y; Denny WA; Wilson WR; Patterson AV
Cancer Gene Ther; 2007 Dec; 14(12):953-67. PubMed ID: 17975564
[TBL] [Abstract][Full Text] [Related]
39. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
40. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]